Gilead’s New HIV Treatment Shows Promise in Trials | Low Discontinuation Rates
Gilead Sciences announced promising results on Wednesday, , regarding its experimental single-tablet HIV treatment. The new regimen appears to be well-tolerated by patients and demonstrates low rates of discontinuation, potentially offering a significant advancement in HIV management.
Expanding Treatment Options
For decades, Gilead has been at the forefront of HIV treatment development. The company’s contributions include the first single-tablet regimen for HIV, the first antiretroviral medication for pre-exposure prophylaxis (PrEP), and the first long-acting injectable HIV treatment, administered twice yearly. This latest development builds upon that legacy, aiming to further simplify treatment and improve patient adherence.
The announcement comes as the medical community continues to seek more effective and convenient ways to manage HIV. Current treatment typically involves daily oral medications, which, while highly effective at suppressing the virus, can present challenges for some individuals in terms of adherence and potential side effects. A single-tablet option with a favorable tolerability profile could address these concerns.
Promising Trial Data
While specific details of the clinical trials were not fully disclosed in the initial announcement, Gilead indicated that the experimental treatment showed low discontinuation rates
. This suggests that patients were able to continue taking the medication without experiencing intolerable side effects or other reasons for stopping treatment. Low discontinuation rates are crucial for maintaining viral suppression and preventing the development of drug resistance.
The development of this single-tablet regimen is particularly noteworthy given the ongoing research into long-acting therapies. Gilead is also investigating a long-acting, twice-yearly treatment regimen combining lenacapavir and broadly neutralizing antibodies (bNAbs). This investigational therapy achieved its primary endpoint in a Phase 2 study and has received Breakthrough Therapy Designation from the Food and Drug Administration (FDA), signaling its potential to address unmet medical needs.
Progress Towards a Cure
Gilead’s research extends beyond treatment and prevention to encompass the pursuit of a cure for HIV. At the Conference on Retroviruses and Opportunistic Infections (CROI) 2025, the company presented data from the first HIV cure clinical trial conducted in South Africa. While a cure remains a complex challenge, these ongoing efforts represent a significant step forward in understanding the virus and developing strategies to eliminate it from the body.
Addressing Global Access
Gilead has also demonstrated a commitment to expanding access to HIV prevention and treatment in low-income countries. In , the company pledged to supply its twice-yearly HIV prevention injection, lenacapavir, to these regions if it receives U.S. Approval, despite uncertainties surrounding funding from the President’s Emergency Plan for AIDS Relief (PEPFAR). This commitment underscores the importance of global collaboration in combating the HIV epidemic.
The potential rollout of lenacapavir in low-income countries is contingent upon both FDA and World Health Organization (WHO) approval. If approved, the injections could begin reaching approximately 2 million people in 18 countries as early as . Gilead has agreed to provide the drug at cost for two to three years, allowing generic manufacturers to ramp up production and ensure sustainable access.
Looking Ahead
The announcement of this experimental single-tablet HIV treatment, alongside ongoing research into long-acting therapies and a potential cure, highlights the continued progress in the field of HIV medicine. Jared Baeten, MD, PhD, Senior Vice President, Virology Therapeutic Area Head at Gilead, emphasized the company’s dedication to scientific discovery
and expanding choices and enhancing outcomes for those with HIV
.
The development of more convenient and tolerable treatment options, coupled with efforts to improve global access, offers hope for further reducing the burden of HIV and ultimately ending the epidemic. Further details regarding the specific composition of the single-tablet regimen, the results of the clinical trials, and the timeline for potential FDA approval are anticipated in the coming months.
Here’s an experimental treatment, and further research is needed to fully evaluate its long-term efficacy, and safety. Individuals currently receiving HIV treatment should continue to follow the guidance of their healthcare providers and not make any changes to their medication regimen without consulting a medical professional.